Literature ReviewDiagnosis and Treatment of Isolated Cerebral Mucormycosis: Patient-Level Data Meta-Analysis and Mayo Clinic Experience
Introduction
The first documented description of mucormycosis involving the central nervous system was published in 1885 by Paltauf,1 who coined the term “mycosis mucorina.” The nomenclature for these infections has varied and has included mucormycosis, zygomycosis, and phycomycosis.2 The causative fungi belong to the order Mucorales with the predominant genera being Rhizopus and Mucor, followed by Lichtheimia, Rhizomucor, Saksenaea, Cunninghamella, and Apophysomyces.3, 4, 5, 6, 7, 8 These organisms are found almost ubiquitously in soil and decomposing organic matter. The most important aspect of immune function in neutralizing spores or hyphae has been shown experimentally and clinically to be phagocytic activity.9 Patients with either severe neutropenia or severely inhibited neutrophil function are at greater risk of mucormycosis than patients with impaired T-cell immunity.10, 11
Rhinocerebral mucormycosis is a well-described entity that is typically characterized by gray and/or erythematous lesions with black eschars in the nasal and palatal region. The highly angioinvasive fungi can rapidly spread into the brain parenchyma, causing lesions primarily in the frontal and temporal lobes, and are associated with mortality rates as high as 96%.7, 12 However, isolated involvement of the brain is extremely rare, and only sporadic cases have been reported.7 Isolated cerebral infections have been hypothesized to be caused by direct inoculation of spores present either in drugs of abuse or in the cutting agents.13 The pathologic features pose substantial diagnostic challenges that hinder timely diagnosis and administration of therapy, increasing mortality dramatically.
Given the rarity of isolated cerebral mucormycosis, no established guidelines exist to assist clinicians with the best management approach. One solution would be pooling and analyzing data from all studies reported to date. Therefore, we reviewed the reported data and provide a comprehensive meta-analysis of individual-level data of all reported studies. We also report an unpublished case from our institution.
Section snippets
Search Strategy and Selection Criteria
A comprehensive search was conducted of the following databases from their inception through March 31, 2018: PubMed, Ovid MEDLINE Epub Ahead of Print, Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and the search was conducted by an experienced librarian with input from the present study's principal investigators
Results
For our present review, we followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Supplemental Figure 1). Our initial search yielded 2552 results spanning publication years 1885 through March 31, 2018, of which 130 reports (141 patients) met the eligibility criteria and were screened in full text for inclusion. Of the 141 total patients, 74 (52.5%) were excluded (Supplemental Table 3 and Supplemental References). A total of 56 studies with 67 patients
Discussion
Isolated cerebral mucormycosis is challenging to diagnose and to treat and, although rare, is estimated to account for ∼8% of all mucormycosis cases.7 To decrease the mortality associated with this potentially fatal disease, mucormycosis needs to be identified earlier and treated quickly with antifungal agents. From the present review of 68 cases, we found that amphotericin B and stereotactic aspiration use were associated with a significant decrease in patient mortality, and lesion location in
Conclusions
Isolated cerebral mucormycosis is a rare cause of intracranial abscess. The prognosis is grave, and ∼65% of patients will die. A high level of suspicion is needed for patients with a history of IVDA who have non–contrast-enhancing lesions in the basal ganglia and rapidly progressing symptoms, especially hemiparesis. Given the significant survival benefit for patients who receive amphotericin B, we suggest early stereotactic aspiration should be performed in such cases to obtain tissue for
Acknowledgments
The authors thank Larry J. Prokop, M.L.S., for his assistance with the electronic literature search. The authors also thank Leah Voit-Ostricki for her assistance in preparing the figures.
References (74)
- et al.
Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment
Clin Microbiol Infect
(2004) Zygomycosis: conventional laboratory diagnosis
Clin Microbiol Infect
(2009)- et al.
Mucormycoses
Infect Dis Clin North Am
(2016) - et al.
MR imaging in rhinocerebral and intracranial mucormycosis with CT and pathologic correlation
Magn Reson Imaging
(1992) - et al.
Cerebral cladosporiosis
Surg Neurol
(1981) - et al.
Primary phycomycosis of the brain in heroin addicts
Surg Neurol
(1987) - et al.
Zygomycosis of the basal ganglia in intravenous drug users
Am J Med
(1989) - et al.
Isolated cerebral mucormycosis: report of a case and review of the literature
J Neurol Sci
(2006) - et al.
Successful treatment of a giant isolated cerebral mucormycotic (zygomycotic) abscess using endoscopic debridement: case report and therapeutic considerations
Surg Neurol
(2008) - et al.
Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess
J Clin Neurosci
(2014)
Isolated cerebral mucormycosis of the basal ganglia
Clin Neurol Neurosurg
Looks like a stroke, acts like a stroke, but it's more than a stroke: a case of cerebral mucormycosis
J Stroke Cerebrovasc Dis
A cryptic case: isolated cerebral mucormycosis
Am J Med
Mycosis mucorina Ein Beitrag zur Kenntniss der menschlichen Fadenpilzerkrankungen
Arch Pathol Anat Archiv Pathol Anat Physiol Klin Med
Epidemiology and clinical manifestations of mucormycosis
Clin Infect Dis
Zygomycetes in human disease
Clin Microbiol Rev
Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review
Clin Infect Dis
Epidemiology and outcome of zygomycosis: a review of 929 reported cases
Clin Infect Dis
Pneumonia with Cunninghamella species in patients with hematologic malignancies: a case report and review of the literature
Cancer
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Latest Developments in Influenza, with accompanying Clinics Review Articles
Pathogenesis of mucormycosis
Clin Infect Dis
A 28-year-old i.v. drug user with bilateral basal ganglia and brainstem lesions
Neurology
Primary cerebral mucormycosis: a case report and literature review
Neurologist
The meaning and use of the area under a receiver operating characteristic (ROC) curve
Radiology
Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases
Medicine (Baltimore)
Intracranial phycomycosis: case reports
Neurosurgery
Cerebral mucormycosis: report of a case
AMA Arch Pathol
Mucormycosis of the central nervous system
Can Med Assoc J
A case of cerebral mucormycosis diagnosed in life, with eventual recovery
J Clin Pathol
Phycomycosis: a clinicopathologic study of fifty-one cases
Lab Invest
The neuropathologic complications of narcotics addiction
Bull N Y Acad Med
Cerebral phycomycosis in a heroin addict
Neurology
Phycomycosis complicating leukemia and lymphoma
Ann Intern Med
Cerebral mucormycosis and renal aspergillosis in heroin addicts without endocarditis
Am J Med Sci
Cryptic cerebral phycomycosis
Ann Intern Med
Mucormycosis presenting as positional nystagmus and hydrocephalus: case report
J Neurosurg
Zygomycetes brain abscesses in narcotic addicts with serological diagnosis
JAMA
Cited by (0)
Conflict of interest statement: Funding for the present study was provided in part through a grant from Mayo Clinic Health System–Franciscan Healthcare Foundation and the Mayo Foundation of Mayo Clinic. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Dr. Watts is a consultant for Medtronic Spine and Biologics.
Panagiotis Kerezoudis and Charles R. Watts contributed equally to this work and share first authorship.